CEO Executive AssistantCDMO partnership management pharma CEOs navigate is a domain where the stakes are high and the CEO’s direct involvement is often lower than it should be at critical moments – and higher than it needs to be at routine moments. Contract development and manufacturing organizations are increasingly central to pharmaceutical supply chains, particularly for biologics and cell and gene therapy products. When CDMO partnerships work well, they provide world-class manufacturing capability, supply reliability, and regulatory compliance at cost structures that internal manufacturing often cannot match. When they fail, they threaten product launches, create regulatory exposure, and can delay or derail programs that represent years of development investment.
The CEO’s job in CDMO oversight is to ensure the right partnerships are in place, that strategic CDMO relationships are managed at the right level, and that your organization has the internal capability to govern external manufacturing partners effectively.
Why CDMO Relationships Require CEO Awareness
Many pharma CEOs treat CDMO relationships as operational matters fully delegated to supply chain, technical operations, and manufacturing leadership. This is appropriate for routine operational management. But there are specific dimensions of CDMO relationships that have strategic implications requiring CEO-level awareness and, at key moments, CEO-level engagement.
Supply concentration risk: If a single CDMO manufactures your lead product and that relationship fails, your entire commercial supply is at risk. CEOs need to understand the concentration risk in their manufacturing network and ensure that contingency strategies exist.
Regulatory compliance dependency: Your CDMO’s quality systems are your regulatory responsibility. An FDA warning letter at your CDMO is effectively a warning letter about your supply chain. CEOs need to be confident that their CDMO oversight program is rigorous enough to detect quality problems before regulators do.
Strategic relationships in capacity-constrained modalities: In gene therapy, cell therapy, and certain advanced biologics, CDMO capacity is genuinely scarce. The CEO’s personal relationship with senior CDMO leadership can determine whether your company gets priority capacity, favorable contract terms, and early visibility into process development advances.
Deal terms with long-term financial impact: Long-term manufacturing agreements with CDMOs can lock in volume commitments, pricing structures, and technology transfer terms that affect your financial model for years. These are board-level financial commitments that require CEO oversight.
The CEO’s CDMO Engagement Framework
Tier Your CDMO Relationships
Not all CDMOs in your portfolio require the same level of CEO engagement. Tier them by strategic importance:
Tier 1: CDMOs manufacturing your commercial products, CDMOs manufacturing your lead clinical programs approaching pivotal trials, and CDMOs with whom you have entered strategic long-term agreements or equity relationships. CEO engagement is warranted at key milestones and relationship reviews.
Tier 2: CDMOs supporting early clinical programs, CDMOs providing specific analytical or formulation services, and CDMOs used for backup or surge capacity. Your Head of Technical Operations manages these relationships, with CEO visibility through portfolio manufacturing reviews.
Annual Strategic CDMO Reviews
For each Tier 1 CDMO, conduct an annual strategic relationship review at the CEO-to-CEO or CEO-to-President level. This 90-minute session covers: relationship status and satisfaction on both sides, upcoming programs and capacity planning, quality performance and any compliance concerns, and the long-term partnership roadmap.
These sessions accomplish two things: they surface issues that operational-level discussions have not resolved, and they signal to CDMO leadership that your company values the relationship enough to invest CEO time in it. Both effects improve the relationship.
Your Head of Technical Operations or Chief Manufacturing Officer prepares you for these sessions with a factual brief: what is our volume and revenue history with this CDMO, what is their quality scorecard, what are the outstanding contract or performance issues, and what is the objective for the meeting?
Contract and Capacity Decision Points
When you are negotiating a new long-term manufacturing agreement or a significant expansion of an existing CDMO relationship, the contract terms require CEO review. Minimum purchase commitments, pricing escalation structures, technology transfer provisions, and termination rights all have material financial implications.
Your legal, supply chain, and finance teams negotiate the terms. The CEO’s role is to review the final negotiated terms against the company’s strategic requirements before signing. For agreements involving commitments above a defined financial threshold or involving novel technology transfer, bring the contract to the board for approval.
The Quality Oversight Dimension
CDMO quality oversight is a regulatory and operational responsibility that primarily belongs to your quality and manufacturing leadership. But the CEO has a specific accountability: ensuring your organization has robust CDMO oversight capability.
The minimum viable CDMO oversight program includes:
- Annual on-site audits of Tier 1 CDMOs by your quality team
- Defined quality metrics and performance scorecards reviewed quarterly
- Escalation protocols that bring serious quality observations to the CEO’s attention
- Clear contractual requirements for CDMO notification of quality events within defined timeframes
If your organization does not have dedicated CDMO oversight resources – quality engineers with the time and expertise to audit and monitor manufacturing partners – you are carrying regulatory and supply risk that no contract language can fully mitigate. This is a CEO investment decision.
When your quality team reports a significant CDMO quality finding – a process deviation that affects product quality, an FDA observation during a CDMO inspection, or a manufacturing failure that requires investigation – the CEO should be briefed within 24 hours. You do not manage the quality response personally, but you need to know about it because it may affect your regulatory submissions, your commercial supply, and potentially your FDA or EMA notification obligations.
CDMO Partnerships and Pipeline Planning
One of the most common CDMO planning failures is poor coordination between pipeline progress and manufacturing readiness. A clinical program can progress through Phase II rapidly while the manufacturing tech transfer to the commercial CDMO runs months behind, creating a gap at the most critical pre-launch period.
Ensure your pipeline review cadence explicitly includes manufacturing readiness as a gate criterion at each phase transition. A program that is ready to enter Phase III but whose manufacturing supply chain has not been established for the larger scale needed is not truly Phase III ready.
The CEO’s role in this integration is not to manage the technical transfer timeline, but to ensure that manufacturing readiness is surfaced in pipeline reviews – and that resource or timeline gaps between clinical progress and manufacturing readiness trigger the decisions needed to close them.
Cell and Gene Therapy CDMO Complexity
Cell and gene therapy products present CDMO management challenges that differ significantly from traditional biologics. Manufacturing capacity is genuinely scarce globally. Process development at CDMOs must be more deeply integrated with your scientific team because manufacturing processes are less standardized. Regulatory requirements for process characterization are more demanding.
CEOs running cell or gene therapy companies should treat their Tier 1 CDMO relationship as a strategic partnership, not just a vendor arrangement. This may mean equity investments in CDMO capacity, joint process development arrangements, or long-term capacity reservation agreements that ensure supply continuity for a product that cannot easily switch manufacturing partners.
These are substantial financial commitments that require board visibility and CEO ownership. The board reporting pharma function should include manufacturing partnership strategy and supply chain risk as regular agenda items for companies with complex CDMO dependencies.
Building Internal CDMO Governance Capability
The most persistent source of CDMO management failure is inadequate internal capability: companies that have outsourced manufacturing without maintaining the internal expertise to govern the outsourced relationship. When your internal team cannot independently evaluate whether a CDMO’s process deviation is serious or routine, cannot assess whether a CDMO’s proposed manufacturing change requires regulatory notification, or cannot conduct a meaningful quality audit, you have a governance gap.
Invest in CDMO governance capability as a deliberate organizational capability: technical experts with deep manufacturing and quality knowledge who own the CDMO oversight function, not as administrative oversight but as genuine technical collaboration and quality management.
Conclusion
CDMO partnership management pharma CEO oversight requires clarity about which decisions and relationships are genuinely strategic and which are operational. CEO time is well spent at annual strategic relationship reviews with Tier 1 CDMOs, at major contract decision points, and in ensuring your organization has the internal capability to govern manufacturing partners rigorously. Between those moments, an experienced technical operations team with clear authority and a structured quality oversight program is the right solution. The CEOs who get this right treat CDMO relationships as what they are: strategic partnerships that determine whether your best clinical programs can be delivered to patients.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.